Share

Effect of lansoprazole on the epigastric symptoms of functional dyspepsia (ELF study): A multicentre, prospective, randomized, double-blind, placebo-controlled clinical trial.

Hidekazu Suzuki, Hiroaki Kusunoki, Takeshi Kamiya, Seiji Futagami, Yasuharu Yamaguchi, Toshihiro Nishizawa, Eisuke Iwasaki, Juntaro Matsuzaki, Shinichi Takahashi, Choitsu Sakamoto, Ken Haruma, Takashi Joh, Keiko Asakura, Toshifumi Hibi

PAPERpubmedUnited European gastroenterology journal2013randomized trialEffect: benefitEvidence: Moderate

Abstract

BACKGROUND: Since the publication of the Rome III criteria for functional dyspepsia (FD), the evidence about the efficacy of half-dose of proton pump inhibitors for dyspepsia symptoms have been limited. OBJECTIVE: To examine the efficacy of lansoprazole for functional dyspepsia (FD) diagnosed with the Rome III criteria by the multicentre, double-blind, randomized, placebo-controlled study in Japan. METHODS: A total of 54 FD participants were randomized to lansoprazole 15 mg once daily or placebo for a 4-week double-blind treatment period. The primary efficacy endpoint was an overall dyspeptic symptom relief rate evaluated by 5-point Likert scale scores. The alteration of dyspeptic symptom scores during the study period was also assessed. RESULTS: At week 4, the overall dyspeptic symptom relief rates were higher in the lansoprazole group (30.4%) than in the placebo group (6.7%) (p = 0.045). The scores for epigastric pain (p = 0.045) and epigastric burning (p = 0.03) were significantly improved in the lansoprazole group compared to the placebo group, whereas the improvement of the scores for postprandial fullness (p = 0.81) and early satiation (p = 0.33) was not different between lansoprazole and placebo groups. CONCLUSIONS: Lansoprazole 15 mg ameliorates dyspeptic symptoms, particularly the epigastric pain syndrome-related symptoms of FD.

AI evidence extraction

At a glance
Study type
randomized trial
Effect direction
benefit
Population
Participants with functional dyspepsia (FD) diagnosed with the Rome III criteria in Japan
Sample size
54
Exposure
4-week double-blind treatment period
Evidence strength
Moderate
Confidence: 74% · Peer-reviewed: yes

Main findings

At week 4, overall dyspeptic symptom relief was higher with lansoprazole 15 mg once daily (30.4%) than placebo (6.7%) (p=0.045). Epigastric pain (p=0.045) and epigastric burning (p=0.03) improved significantly versus placebo, while postprandial fullness (p=0.81) and early satiation (p=0.33) did not differ between groups.

Outcomes measured

  • Overall dyspeptic symptom relief rate (5-point Likert scale)
  • Epigastric pain score
  • Epigastric burning score
  • Postprandial fullness score
  • Early satiation score

Limitations

  • Small sample size (n=54)
  • Short treatment duration (4 weeks)
View raw extracted JSON
{
  "study_type": "randomized_trial",
  "exposure": {
    "band": null,
    "source": null,
    "frequency_mhz": null,
    "sar_wkg": null,
    "duration": "4-week double-blind treatment period"
  },
  "population": "Participants with functional dyspepsia (FD) diagnosed with the Rome III criteria in Japan",
  "sample_size": 54,
  "outcomes": [
    "Overall dyspeptic symptom relief rate (5-point Likert scale)",
    "Epigastric pain score",
    "Epigastric burning score",
    "Postprandial fullness score",
    "Early satiation score"
  ],
  "main_findings": "At week 4, overall dyspeptic symptom relief was higher with lansoprazole 15 mg once daily (30.4%) than placebo (6.7%) (p=0.045). Epigastric pain (p=0.045) and epigastric burning (p=0.03) improved significantly versus placebo, while postprandial fullness (p=0.81) and early satiation (p=0.33) did not differ between groups.",
  "effect_direction": "benefit",
  "limitations": [
    "Small sample size (n=54)",
    "Short treatment duration (4 weeks)"
  ],
  "evidence_strength": "moderate",
  "confidence": 0.74,
  "peer_reviewed_likely": "yes",
  "keywords": [
    "functional dyspepsia",
    "Rome III criteria",
    "lansoprazole",
    "proton pump inhibitor",
    "randomized",
    "double-blind",
    "placebo-controlled",
    "epigastric pain syndrome"
  ],
  "suggested_hubs": []
}

AI can be wrong. Always verify against the paper.

AI-extracted fields are generated from the abstract/metadata and may be incomplete or incorrect. This content is for informational purposes only and is not medical advice.

Comments

Log in to comment.

No comments yet.

NNEMF synthesis

Synthesis pending.

Original record: rfsafe.org paper 3070

Effect of lansoprazole on the epigastric symptoms of functional dyspepsia (ELF study): A multicentre, prospective, randomized, double-blind, placebo-controlled clinical trial. · Non-native EMF